Clinical trial
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis (CONSONANCE)
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis (CONSONANCE)
ClinicalTrials.gov ID: NCT03523858
Sponsor: Hoffmann-La Roche
Information provided by: Hoffmann-La Roche (Responsible Party)
Last Update Posted: 2023-08-31
Brief Summary:
This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).
OFFICIAL TITLE:
An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple Sclerosis.
INTERVENTION / TREATMENT:
Drug: Ocrelizumab
| Category | Value |
|---|---|
| Study Start (Actual) | 2018-05-28 |
| Primary Completion (Estimated) | 2026-01-15 |
| Study Completion | 2026-12-04 |
| Enrollment (Actual) | 927 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers | MN39159 |